BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Carb-X - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://carb-x.org
X-WR-CALDESC:Events for Carb-X
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210105
DTEND;VALUE=DATE:20210106
DTSTAMP:20260403T200204
CREATED:20201202T233712Z
LAST-MODIFIED:20201202T233753Z
UID:4672-1609804800-1609891199@carb-x.org
SUMMARY:National Academy of Science
DESCRIPTION:The National Academy of Sciences (NAS) is a private\, nonprofit organization of the country’s leading researchers. The NAS recognizes and promotes outstanding science through election to membership; publication in its journal\, PNAS; and its awards\, programs\, and special activities. Through the National Academies of Sciences\, Engineering\, and Medicine\, the NAS provides objective\, science-based advice on critical issues affecting the nation. \nCARB-X participants include Kevin Outterson\, Executive Director. \nClick here to learn more.
URL:https://carb-x.org/event/national-academy-of-science/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210114T110000
DTEND;TZID=America/New_York:20210114T123000
DTSTAMP:20260403T200204
CREATED:20201215T155536Z
LAST-MODIFIED:20201215T155536Z
UID:4822-1610622000-1610627400@carb-x.org
SUMMARY:Live Webinar: GARDP/REVIVE – Manipulating the host response to treat infections
DESCRIPTION:Immune modulation and host directed therapies as an adjunctive approach to treating infections (R.E.W. (Bob) Hancock):  \n\nHost defence peptides (HDP; often termed antimicrobial peptides) stimulate protective immunity while suppressing potentially harmful inflammation. Both of these activities can assist in anti-infective therapy.\nHDPs work as immune modulators in animal models against ESKAPE pathogen\, MDR TB\, fungal\, malaria and viral infections\, as well as sterile inflammation. They are likely to be employed in adjunctive therapy in combination with antibiotics.\nHDPs often have additional value-added activities including action against bacterial biofilms in animal models. This allows them to be utilized to address situations where antibiotics commonly fail.\nAlternative host-directed therapies can be defined for recalcitrant infections using stem cell mutagenesis and systems biology approaches.\n\nRegulation and reprogramming of the innate immune system as alternative to antibiotics (Henk P. Haagsman):  \n\nHost defence peptides (HDP) are immunomodulatory antimicrobials. – Cathelicidin-derived peptides may serve as paradigms to develop anti-inflammatory anti-infectives.\nCathelicidin-derived peptides may be used prophylactically as immunomodulators and adjuvants in veterinary medicine.\nHost-directed therapy may include innate immune training by epigenetic reprogramming. The presentations will be followed by a Q&A session.\n\nSpeakers: R.E.W. (Bob) Hancock\, University of British Columbia (Canada); Henk P. Haagsman\, Utrecht University (Netherlands) \nModerator: Neeloffer Mookherjee\, Departments of Internal Medicine and Immunology\, University of Manitoba (Canada) \nClick here to learn more and register.
URL:https://carb-x.org/event/live-webinar-gardp-revive-manipulating-the-host-response-to-treat-infections/
LOCATION:WEBINAR\, Webinar\, Webinar\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210118
DTEND;VALUE=DATE:20210121
DTSTAMP:20260403T200204
CREATED:20201202T234358Z
LAST-MODIFIED:20201202T234358Z
UID:4671-1610928000-1611187199@carb-x.org
SUMMARY:Keystone Symposia: Harnessing the Microbiome for Disease Prevention and Therapy
DESCRIPTION:Joint meeting with: The Microbiome: From Mother to Child\nJanuary 18-20\, 2021 | 10:00AM EST | 3:00PM UTC | 4:00PM CET* \nOur understanding of the microbiome is advancing rapidly\, and continues to productively move through the discovery phase\, with numerous correlations being established between specific commensal microbes or microbiota compositions and a wide range of diseases that includes infections\, inflammatory conditions\, metabolic disease\, autoimmunity and neurologic syndromes. The initial discovery of these potentially important correlations has led many laboratories around the world to probe the molecular mechanisms that form the causal link between specific commensal microbes and disease development\, progression and resolution. Although there have been great advances\, culturing many of the prevalent and metabolically active obligate anaerobic commensals remains a challenge. Exciting advances\, however\, are emerging from laboratories developing tools to genetically manipulate key commensal organisms\, facilitating experimental studies that are identifying the small\, bioactive molecules they produce\, some of which have therapeutic potential. Studies of the impact of bacteriophage on the microbiota also suggest that they may have therapeutic potential. This Keystone conference will focus on recent advances that demonstrate\, at the cellular and molecular level\, the impact of the microbiota and its products on disease susceptibility/resistance\, with an emphasis on microbial and host metabolism\, inter-microbial interactions and the amelioration of diseases. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/keystone-symposia-harnessing-the-microbiome-for-disease-prevention-and-therapy/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210121
DTEND;VALUE=DATE:20210122
DTSTAMP:20260403T200204
CREATED:20201202T233345Z
LAST-MODIFIED:20201207T214641Z
UID:4666-1611187200-1611273599@carb-x.org
SUMMARY:Innovative Medicines Initiative (IMI) ENABLE Annual Meeting
DESCRIPTION:Antimicrobial resistance (AMR) is a major public health threat. Infections caused by resistant bacteria are increasing and causing Europe to face soaring costs both in terms of lives and public health expenditure. Despite the strong need for new antimicrobials\, very few new\, effective antibiotics have been brought to the market in the last decades. The ENABLE project\, within IMI’s New Drugs for Bad Bugs (ND4BB) programme\, is working to advance the development of potential antibiotics against Gram-negative bacteria\, such as Escherichia coli. The ultimate goal of the project is to develop attractive antimicrobial candidates for testing in the clinic\, bringing the possibility of new antibiotics to treat Gram-negative infections one step closer to patients. \nCARB-X participants include Erin Duffy\, Chief of R&D.  \nClick here to learn more.
URL:https://carb-x.org/event/innovative-medicines-initiative-imi-enable-annual-meeting-emd/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210126
DTEND;VALUE=DATE:20210129
DTSTAMP:20260403T200204
CREATED:20201202T234806Z
LAST-MODIFIED:20201207T214811Z
UID:4670-1611619200-1611878399@carb-x.org
SUMMARY:4th Annual Texas Medical Center Antimicrobial Resistance and Stewardship Conference
DESCRIPTION:Please make plans to join us for this outstanding line-up of internationally-renowned experts in antimicrobial resistance and stewardship. \nClick here to learn more.\nClick here to view the agenda.\nClick here to register.
URL:https://carb-x.org/event/skip-to-content-4th-annual-texas-medical-center-antimicrobial-resistance-and-stewardship-conference/
LOCATION:VIRTUAL EVENT
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210127
DTEND;VALUE=DATE:20210130
DTSTAMP:20260403T200204
CREATED:20201022T172818Z
LAST-MODIFIED:20201022T172818Z
UID:4503-1611705600-1611964799@carb-x.org
SUMMARY:5th Microbiome Movement - Drug Development Summit Europe 2021
DESCRIPTION:Participants include CARB-X funded companies Eligo Bioscience and Seres Therapeutics. \nAs the first microbiome-based therapeutic steps closer to market approval\, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic\, biomarker and diagnostic development. Despite this progress\, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them. \nPart of the foremost conference series for microbiome researchers in industry\, the 5th Microbiome Movement – Drug Development Europe 2021 will return to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease\, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes. \nTo learn more\, click here.\nTo view the program\, click here.\nTo register\, click here.
URL:https://carb-x.org/event/5th-microbiome-movement-drug-development-summit-europe-2021/
END:VEVENT
END:VCALENDAR